Terms: = Brain cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
132 results:
1. BRAF and ret polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract] [Full Text] [Related]
2. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
3. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
4. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic strategy using novel ret/YES1 dual-target inhibitor in lung cancer.
Choi YJ; Choi M; Park J; Park M; Kim MJ; Lee JS; Oh SJ; Lee YJ; Shim WS; Kim JW; Kim MJ; Kim YC; Kang KW
Biomed Pharmacother; 2024 Feb; 171():116124. PubMed ID: 38198957
[TBL] [Abstract] [Full Text] [Related]
6. Clinical evidence and adverse event management update of patients with ret- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract] [Full Text] [Related]
7. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in
Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;
N Engl J Med; 2023 Nov; 389(20):1839-1850. PubMed ID: 37870973
[TBL] [Abstract] [Full Text] [Related]
8. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
9. Survival Outcomes of Advanced Thyroid cancer Enriched in brain Metastases Following Treatment With Small Molecule Inhibitors.
Wu SS; Lamarre ED; Scharpf J; Prendes B; Ku JA; Silver N; Burkey B; Woody N; Campbell SR; Yilmaz E; Koyfman SA; Geiger J
Endocr Pract; 2023 Nov; 29(11):881-889. PubMed ID: 37597577
[TBL] [Abstract] [Full Text] [Related]
10. Genomic Alterations and the Incidence of brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Gillespie CS; Mustafa MA; Richardson GE; Alam AM; Lee KS; Hughes DM; Escriu C; Zakaria R
J Thorac Oncol; 2023 Dec; 18(12):1703-1713. PubMed ID: 37392903
[TBL] [Abstract] [Full Text] [Related]
11. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract] [Full Text] [Related]
12. Synthesis and Biological Evaluation of a Library of Sulfonamide Analogs of Memantine to Target Glioblastoma.
Philo JE; Caudle JD; Moussa RN; Kampmeyer PM; Hasin TR; Seo DK; Sheaff RJ; Lamar AA
ChemMedChem; 2023 Aug; 18(16):e202300134. PubMed ID: 37248422
[TBL] [Abstract] [Full Text] [Related]
13. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung cancer with Rearranged during Transfection (ret) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract] [Full Text] [Related]
14. ret signaling in breast cancer therapeutic resistance and metastasis.
Pecar G; Liu S; Hooda J; Atkinson JM; Oesterreich S; Lee AV
Breast Cancer Res; 2023 Mar; 25(1):26. PubMed ID: 36918928
[TBL] [Abstract] [Full Text] [Related]
15. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract] [Full Text] [Related]
16. Central Nervous System Disease in Patients With ret Fusion-Positive NSCLC Treated With Selpercatinib.
Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
[TBL] [Abstract] [Full Text] [Related]
17. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
18. Aerobic exercise combined with resistance exercise training improves cardiopulmonary function and blood lipid of patients with breast cancer: A systematic review and meta-analysis.
Kong L; Gao R
Medicine (Baltimore); 2022 Dec; 101(51):e32391. PubMed ID: 36595800
[TBL] [Abstract] [Full Text] [Related]
19. An overview of the role of selpercatinib and pralsetinib in ret-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract] [Full Text] [Related]
20. Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
Keck MK; Sill M; Wittmann A; Joshi P; Stichel D; Beck P; Okonechnikow K; Sievers P; Wefers AK; Roncaroli F; Avula S; McCabe MG; Hayden JT; Wesseling P; Øra I; Nistér M; Kranendonk MEG; Tops BBJ; Zapotocky M; Zamecnik J; Vasiljevic A; Fenouil T; Meyronet D; von Hoff K; Schüller U; Loiseau H; Figarella-Branger D; Kramm CM; Sturm D; Scheie D; Rauramaa T; Pesola J; Gojo J; Haberler C; Brandner S; Jacques T; Sexton Oates A; Saffery R; Koscielniak E; Baker SJ; Yip S; Snuderl M; Ud Din N; Samuel D; Schramm K; Blattner-Johnson M; Selt F; Ecker J; Milde T; von Deimling A; Korshunov A; Perry A; Pfister SM; Sahm F; Solomon DA; Jones DTW
Acta Neuropathol; 2023 Jan; 145(1):49-69. PubMed ID: 36437415
[TBL] [Abstract] [Full Text] [Related]
[Next]
